Acasti Pharma, Inc (ACST)

[Mkc12five]

Secondary end points would not be reported if primary was not met. My take is that the "May" report secondary endpoints is that some might be available and others not at the time of delievering of topline data. I am not expecting HbA1c will be available. The last patient dosed was on or about 11/26 and HbA1c testing requires a 3 month time gap so earliest on this person would be 2/26 and thus the March timeframes given by the company. Personally i like holding off on all secondary endpoints so they can be given context. A miss on one or 2 might give the shorts an oppertunity to spin this. The 800lb gorilla is going to be LDLc and HbA1c. HDLc was Damn close with a p=.07. So if we can real that one in to p=.05 or less alongside the others then 8B is a good starting point on any BO negotiation.